Rafferty Asset Management
APGE

Rafferty Asset Management’s Apogee Therapeutics APGE Stock Holding History

Rafferty Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.43M Sell
33,369
-27,028
-45% -$2.44M 0.01% 393
2026
Q1 		$5.08M Buy
60,397
+11,778
+24% +$855K 0.02% 351
2025
Q4 		$3.67M Sell
48,619
-17,177
-26% -$1.08M 0.01% 515
2025
Q3 		$2.61M Buy
65,796
+23,585
+56% +$901K 0.01% 582
2025
Q2 		$1.83M Sell
42,211
-790
-2% -$30.1K 0.01% 620
2025
Q1 		$1.61M Sell
43,001
-14,672
-25% -$567K 0.01% 626
2024
Q4 		$2.61M Buy
57,673
+3,110
+6% +$159K 0.01% 567
2024
Q3 		$3.21M Sell
54,563
-20,275
-27% -$971K 0.01% 520
2024
Q2 		$2.94M Buy
74,838
+8,710
+13% +$423K 0.01% 533
2024
Q1 		$4.39M Buy
+66,128
New +$2.89M 0.02% 502

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Rafferty Asset Management's APGE Position: Q2 2026 in Review

Rafferty Asset Management reduced its Apogee Therapeutics (APGE) stake by 45% in Q2 2026, selling an estimated $2.44M and leaving 33,369 shares worth $4.43M. The position accounts for 0.01% of the portfolio, ranked #393.

Rafferty Asset Management first reported a position in APGE in Q1 2024 and has held it in 10 quarters since. The position peaked at $5.08M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Rafferty Asset Management held 33,369 shares of Apogee Therapeutics worth $4.43M as of Q2 2026.
  • Rafferty Asset Management sold 27,028 Apogee Therapeutics shares in Q2 2026, an estimated $2.44M.
  • Apogee Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #393 holding.
  • Rafferty Asset Management first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Rafferty Asset Management's Apogee Therapeutics position peaked at $5.08M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.